Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Tirzepatide tends to be the better fit when: the goal is more significant weight loss (15 percent or more of body weight), the patient has type 2 diabetes with A1C above target on prior therapies, prior single-pathway GLP-1 use produced limited results, or the patient tolerated GLP-1s reasonably well and wants a stronger next step
This is typically when cycles end
FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014
Variable subcutaneous fat depth raises the chance of accidentally injecting into muscle
Oral GLP-1s (Lillys paltusotine-orforglipron, etc.) are expected in late 2025/2026, and might be covered differently (some plans treat orals less restrictively than injectables)
US$ 23.83
US$ 23.43
US$ 29.70
US$ 23.90
US$ 23.95
US$ 27.88
US$ 28.63
US$ 24.29
US$ 24.53
